

A

08/24/99
1c549 U.S. PTO

Attorney Docket No.: 5442.200-US PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

1c549 U.S. PTO
09/382096
08/24/99

Express Mail Label No. EL293688038US
Date of Deposit August 24, 1999

Sir:

This is a request for filing an application under 37 C.F.R. 1.53(b) of

Applicant(s): Outtrup et al.

Title: **Alkaline Bacillus Amylase**

18 pages of specification 6 sheets of formal drawings
3 sheets of Declaration and Power of Attorney 13 pages of Sequence

[x] The filing fee is calculated as follows:

Basic Fee:	\$ 760.00
Total Claims: 19 - 20 = 0 x 18 =	\$ 0.00
Independent Claims: 3 - 3 = 0 x 78 =	\$ 0.00
Total Fee:	\$ 760.00

Priority of Danish application serial no. 0228/98 filed on February 18, 1998 is claimed under 35 U.S.C. 119. A certified copy will follow.


Priority of U.S. provisional application serial no. 60/146,297 filed on February 27, 1998 is claimed under 35 U.S.C. 119.

The benefit of application no. 09/249,558 filed on February 12, 1999 in the U.S. is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be **\$760**, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: August 24, 1999

Respectfully submitted,

Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

ALKALINE BACILLUS AMYLASE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application no. 09/249,558 filed on February 12, 1999 and claims priority under 35 U.S.C. 119 of Danish application no. 0228/98 filed on February 18, 1998, and U.S. provisional application no. 60/146,297, filed on February 27, 1998, the contents of which are fully incorporated by reference.

FIELD OF INVENTION

The present invention relates to amylases having improved washing performance in an alkaline detergent solution at low temperature.

BACKGROUND OF THE INVENTION

For a number of years α -amylase enzymes have been used for a variety of different purposes, the most important of which are starch liquefaction, textile desizing, starch modification in the paper and pulp industry, and for brewing and baking. A further use of α -amylases, which is becoming increasingly important is the removal of starchy stains during washing with a detergent at alkaline pH.

Examples of commercial α -amylase products are Termamyl®, BAN® and Fungamyl®, all available from Novo Nordisk A/S, Denmark. These and similar products from other commercial sources have an acidic to a neutral pH optimum, typically in the range of from pH 5 to pH 7.5, and they do not display optimal activity in detergent solutions at alkaline pH.

WO 95/26397 discloses an α -amylase from a *Bacillus* strain which has optimum activity at pH 8. WO 96/23873 describes variants of *Bacillus* amylases with improved performance under washing conditions.

US 5,147,796 describes an alkaline pullulanase having alpha-amylase activity. Fig. 2b of the document shows optimum amylase activity at pH 8-8.5.

M. Takagi et al., J. Ferment. Bioeng., vol 81, No. 6, 557-559 (1996) describe an alkaliphilic alpha-amylase-pullulanase from *Bacillus* sp. The enzyme has optimum amylase activity at pH 9, but the activity drops rapidly at higher pH, and the activity at pH 10 is lower than at pH 7.

It is an object of the present invention to provide novel α -amylases with improved performance in alkaline solutions, especially in alkaline detergent solutions at pH around 9-11.

SUMMARY OF THE INVENTION

The present invention provides alpha-amylase which is:

- a) a polypeptide produced by *Bacillus* sp. NCIMB 40916, or
- b) a polypeptide having an amino acid sequence as shown in positions 1-556 of SEQ ID NO: 4, or
- c) a polypeptide encoded by the alpha-amylase encoding part of the DNA sequence cloned into a plasmid present in *Escherichia coli* DSM 13001, or
- d) an analogue of the polypeptide defined in (a) or (b) which:
 - i) is at least 60 % homologous with said polypeptide, or
 - ii) is derived from said polypeptide by substitution, deletion and/or insertion of one or several amino acids.

In an embodiment of the invention the alpha-amylase is the truncated mature alpha-amylase shown in SEQ ID NO: 2 (i.e., amino acids 1-517) encoded by nucleotides 94-1646 of the DNA sequence shown in SEQ ID NO: 1 and deposited as *Escherichia coli* DSM 12662.

In another aspect, the invention provides an α -amylase having one or more of the following characteristics:

- an activity at pH 10.5 which is at least two times higher than the activity at pH 7.3 when measured at 37°C.
- an activity at pH 9.5 which is at least 4 times higher than the activity at pH 7.3 when measured at 37°C.
- an optimum pH of about 9.5 when measured at 37°C.
- a thermostability such that it retains more than 90 % of its activity after 20 minutes incubation at 25°C in a solution of 3 g/l of a test detergent containing 20% STPP, 25% Na₂SO₄, 15% Na₂CO₃, 20% LAS, 5% C12-C15 alcohol ethoxylate, 5% Na₂Si₂O₅, 0.3% NaCl at pH 10.5 and 6 degrees German hardness, and retains less than 90 % of its activity after 20 minutes incubation at 30°C in the same solution.
- a molecular weight of about 55 kDa as determined by SDS-PAGE.
- an iso-electric point of about 5 as determined by isoelectric focusing.

The invention also provides an isolated DNA sequence which encodes an alpha-amylase, wherein the alpha-amylase is that described above, or wherein the DNA sequence comprises:

- a) the DNA sequence shown in positions 94-1764 of SEQ ID NO: 3, or
- b) an analogue of the DNA sequence defined in a) which
 - i) is at least 60 % homologous with said DNA sequence, or
 - ii) hybridizes with said DNA sequence at least 55°C.

Other aspects of the invention provide a recombinant expression vector comprising the DNA sequence, and a cell transformed with the DNA sequence or the recombinant expression vector.

5 The invention also provides a method for producing an alpha-amylase by cultivating the cell and a detergent composition comprising said alpha-amylase.

BRIEF DESCRIPTION OF DRAWINGS

The present invention is further illustrated with reference to the accompanying drawings, in which:

10 Fig. 1 shows a pH activity profile of the amylase from NCIMB 40916 compared to two prior-art amylases (SP722 and Termamyl).

Fig. 2 shows a temperature activity profile of the amylase from NCIMB 40916.

Fig. 3 shows the stability of the amylase from NCIMB 40916 after incubation at various temperatures.

15 Fig. 4 shows the cloning vector pSJ1678 described in Example 1.

Figs. 5 and 6 show results of washing tests described in Example 4.

DETAILED DESCRIPTION OF THE INVENTION

Microbial source

20 The alpha-amylase of the invention may be derived from a strain of *Bacillus*. A preferred strain is *Bacillus* sp. NCIMB 40916. This strain was deposited on 28 January 1998 by the inventors under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at the National Collections of Industrial and Marine Bacteria Limited (NCIMB), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland, United
25 Kingdom. An *Escherichia coli* strain termed JA388 containing the truncated alpha amylase gene shown in SEQ ID NO: 1 cloned in plasmid pJA388 has also been deposited on 3 February 1999 under the terms of the Budapest Treaty with the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig DE, and given the accession
30 number DSM 12662. Further, an *Escherichia coli* strain termed NN049489 containing the full length alpha amylase gene shown in SEQ ID NO: 3 cloned into plasmid pJA386 has also been deposited on 17 August, 1999, under the terms of the Budapest Treaty with the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig DE,
35 and given the accession number DSM 13001. It is believed that SEQ ID NO: 3 and the deposited sequence are identical.

Production of alpha-amylase

The alpha-amylase of the invention can be produced by cultivating a suitable amylase-producing strain of *Bacillus* or the transformed host cell of the invention in a suitable nutrient medium, and recovering the alpha-amylase from the culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the α -amylase of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. as described in catalogues of the American Type Culture Collection).

The α -amylase secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

Properties of alpha-amylase

A preferred alpha-amylase is derived from *Bacillus sp.* NCIMB 40916. It can be produced as described in the examples. The full length amino acid sequence of the amylase and the DNA encoding it are shown in SEQ ID NO: 3 and 4. The DNA and amino acid sequence of the truncated alpha-amylase is shown in SEQ ID NO: 1 and 3, respectively. The following characteristics were found for the full length amylase of the invention (purified alpha-amylase from NCIMB 40916):

A molecular weight of approximately 55 kDa as determined by SDS-PAGE using a Novex, 4-25% gradient gel.

A pI of approximately 5 was determined by isoelectric focusing (Ampholine PAG, pH 3.5-9.5).

A pH-activity curve is shown in Fig. 1, taking the activity at pH 7.3 as 100%. It was determined using the Phadebas assay using 50 mM Britten-Robinson buffer adjusted to various pH-values. For reference, the pH profiles of two prior-art *Bacillus* amylases (Termamyl derived from *B. licheniformis* and SP722 produced according to WO 95/26397) were measured under the same conditions are also shown in Figure 1. Figure 1 shows that the amylase of the invention has about 10 times higher activity than the two prior-art amylases at pH 9.5. Fig. 1 also shows that the optimum activity is about pH 9.5.

A temperature-activity curve was measured using the Phadebas assay at various temperatures with 50 mM Britten-Robinson buffer adjusted to pH 9.5. The

results are shown in Fig. 2. It is seen from Fig. 2 that the amylase of the invention has optimum activity at about 55°C.

Stability of the amylase was measured at pH 10.5 (50 mM CAPS) at 22, 37, 45, 55 and 65 °C after 30 minutes incubation. The enzyme was diluted to 40 NU/ml in buffer and 25 microlitre sample was incubated at the respective temperatures. After 30 minutes, the samples was chilled on ice and residual activity was determined. A stability profile of the amylase of the invention and a prior-art amylase (SP722) is shown in Figure 3.

Stability was tested by incubating 40 NU/ml of amylase in a solution of 3 g/l of the A/P model detergent described above, at pH 10.5 and 6°dH (German hardness, Ca:Mg 2:1). After the incubation, the residual activity was measured by Phadebas at pH 7.3. The results were 95 % residual activity after incubation at 25°C, and 87 % at 30°C.

Homology of polypeptide and DNA sequence

The amino acid sequence homology may be determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art. Thus, FASTA provided in GCG version 8 (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453) may be used with the following settings: Scoring matrix: GenRunData:blosom50.cmp, Variable pamfactor used Gap creation penalty: 12, Gap extension penalty: 2. Alternatively, Gap from GCG version 9 may be used with a translated version 8 peptide scoring matrix, a gap creation penalty of 30, a gap extension penalty of 1 using ntol's matrix (<http://plasmid/~bioweb/matrix/>) without end gap penalty.

The amino acid sequence exhibits a degree of identity preferably of at least 60%, preferably at least 70%, more preferably at least 80%, especially at least 90% or at least 95%, with the amino acid sequence shown in positions 1-556 of SEQ ID NO: 4.

The DNA sequence homology may be determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (described above). Thus, Gap GCGv8 may be used with the following default parameters: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, default scoring matrix . GAP uses the method of Needleman/Wunsch/Sellers to make alignments.

The DNA construct of the present invention comprises a DNA sequence exhibiting a degree of identity preferably of at least 60%, preferably at least 70%, more preferably at least 80%, especially at least 90% or at least 95%, with the nucleic acid sequence shown in positions 94-1764 of SEQ ID NO: 3.

5 Hybridization

The hybridization is used to indicate that a given DNA sequence is analogous to a nucleotide probe corresponding to SEQ ID NO: 3. The hybridization conditions are described in detail below.

Suitable conditions for determining hybridization between a nucleotide probe and a homologous DNA or RNA sequence involves presoaking of the filter containing the DNA fragments or RNA to hybridize in 5 x SSC (standard saline citrate) for 10 min, and prehybridization of the filter in a solution of 5 x SSC (Sambrook et al. 1989), 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 µg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) *Anal. Biochem.* 132:6-13), ³²P-dCTP-labeled (specific activity > 1 x 10⁹ cpm/µg) probe for 12 hours at approx. 45°C. The filter is then washed two times for 30 minutes in 2 x SSC, 0.5 % SDS at a temperature of at least 55°C, more preferably at least 60°C, more preferably at least 65°C, even more preferably at least 70°C, especially at least 75°C.

Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using a x-ray film.

Recombinant expression vector

The expression vector of the invention typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

The recombinant expression vector carrying the DNA sequence encoding the α-amylase of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, a bacteriophage or an extrachromosomal element, minichromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

5 Examples of suitable promoters for directing the transcription of the DNA sequence encoding an α -amylase of the invention, especially in a bacterial host, are the promoter of the *lac* operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis* α -amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase
10 gene (*amyM*), the promoters of the *Bacillus Amyloliquefaciens* α -amylase (*amyQ*), the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral α -amylase, *A. niger* acid stable α -amylase, *A. niger* glucoamylase,
15 *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the α -amylase of the invention. Termination and polyadenylation sequences may suitably be derived from the same
20 sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and
25 pIJ702.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Furthermore, the
30 vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g., as described in WO 91/17243.

While intracellular expression may be advantageous in some respects, e.g. when using certain bacteria as host cells, it is generally preferred that the
35 expression is extracellular.

Procedures suitable for constructing vectors of the invention encoding an α -amylase, and containing the promoter, terminator and other elements, respectively, are well known to persons skilled in the art [cf., for instance, Sambrook et al. (1989)].

Host cells

The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the recombinant production of the α -amylase of the invention. The cell
5 may be transformed with the DNA construct of the invention encoding the amylase, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conven-
10 tional methods, e.g. by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g. a bacterial or a fungal
15 (including yeast) cell.

Examples of bacterial host cells which, on cultivation, are capable of producing the enzyme of the invention are gram-positive bacteria such as strains of *Bacillus*, such as strains of *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. clausii*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*,
20 *B. circulans*, *B. lautus*, *B. megaterium* or *B. thuringiensis*, or strains of *Streptomyces*, such as *S. lividans* or *S. murinus*, or gram-negative bacteria such as *Escherichia coli*. The transformation of the bacteria may be effected by protoplast transformation, electroporation, conjugation, or by using competent cells in a manner known per se (cf. Sambrook et al., supra).

The yeast organism may favourably be selected from a species of *Saccharomyces* or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*. The filamentous fungus may advantageously belong to a species of *Aspergillus*, e.g. *Aspergillus oryzae* or *Aspergillus niger*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed
25 by regeneration of the cell wall in a manner known *per se*. A suitable procedure for transformation of *Aspergillus* host cells is described in EP 238 023.

Industrial Applications

Owing to their activity at alkaline pH values, the α -amylases of the invention are well suited for use in a variety of industrial processes, in particular the enzyme
35 finds potential applications as a component in detergents, e.g. laundry and hard surface cleaning detergent compositions, but it may also be useful in the production of sweeteners and ethanol from starch. Thus, it may be used in conventional starch-

converting processes, such as liquefaction and saccharification processes described in US Patent No. 3,912,590 and EP patent publications Nos. 252,730 and 63,909.

The alkaline α -amylase of the invention may also be used in the production of lignocellulosic materials, such as pulp, paper and cardboard, from starch reinforced waste paper and cardboard, especially where repulping occurs at pH above 7 and where amylases can facilitate the disintegration of the waste material through degradation of the reinforcing starch. The α -amylase of the invention is especially useful in a process for producing a papermaking pulp from starch-coated printed paper. The process may be performed as described in WO 95/14807, comprising the following steps:

- a) disintegrating the paper to produce a pulp,
- b) treating with a starch-degrading enzyme before, during or after step a), and
- c) separating ink particles from the pulp after steps a) and b).

The α -amylases of the invention may also be very useful in modifying starch where enzymatically modified starch is used in papermaking together with alkaline fillers such as calcium carbonate, kaolin and clays. With the alkaline α -amylases of the invention it becomes possible to modify the starch in the presence of the filler thus allowing for a simpler integrated process.

The α -amylase of the invention may also be very useful in textile desizing. In the textile processing industry, α -amylases are traditionally used as auxiliaries in the desizing process to facilitate the removal of starch-containing size which has served as a protective coating on weft yarns during weaving. Complete removal of the size coating after weaving is important to ensure optimum results in the subsequent processes, in which the fabric is scoured, bleached and dyed. Enzymatic starch break-down is preferred because it does not involve any harmful effect on the fiber material. In order to reduce processing cost and increase mill throughput, the desizing processing is sometimes combined with the scouring and bleaching steps. In such cases, non-enzymatic auxiliaries such as alkali or oxidation agents are typically used to break down the starch, because traditional α -amylases are not very compatible with high pH levels and bleaching agents. The non-enzymatic breakdown of the starch size does lead to some fiber damage because of the rather aggressive chemicals used. Accordingly, it would be desirable to use the α -amylases of the invention as they have an improved performance in alkaline solutions. The α -amylases may be used alone or in combination with a cellulase when desizing cellulose-containing fabric or textile.

The α -amylases of the invention may also be very useful in a beer-making process; the α -amylases will typically be added during the mashing process.

Detergent Compositions

According to the invention, the α -amylase may typically be a component of a detergent composition, e.g., a laundry detergent composition. As such, it may be included in the detergent composition in the form of a non-dusting granulate, a stabilized liquid, or a protected enzyme. Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molecular weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in patent GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

The properties of the alpha-amylase of the invention make it particularly suitable for use in alkaline detergents, e.g. at pH 9.5-10.5, and for washing at low temperatures, e.g. 20-40°C.

The detergent composition of the invention may be in any convenient form, e.g. as powder, granules, paste or liquid. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous.

The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or amphoteric (zwitterionic). The detergent will usually contain 0-50% of anionic surfactant such as linear alkylbenzenesulfonate (LAS), alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid, or soap. It may also contain 0-40% of nonionic surfactant such as alcohol ethoxylate (AEO or AE), alcohol propoxylate, carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkylidimethylamine oxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154).

The detergent composition may additionally comprise one or more other enzymes, such as pullulanase, esterase, lipase, cutinase, protease, cellulase, peroxidase, or oxidase, e.g., laccase.

Normally the detergent contains 1-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

The detergent builders may be subdivided into phosphorus-containing and non-phosphorous-containing types. Examples of phosphorus-containing inorganic alkaline detergent builders include the water-soluble salts, especially alkali metal pyrophosphates, orthophosphates, polyphosphates and phosphonates. Examples of non-phosphorus-containing inorganic builders include water-soluble alkali metal carbonates, borates and silicates as well as layered disilicates and the various types of water-insoluble crystalline or amorphous aluminosilicates of which zeolites is the best known representative.

Examples of suitable organic builders include alkali metal, ammonium or substituted ammonium salts of succinates, malonates, fatty acid malonates, fatty acid sulphonates, carboxymethoxy succinates, polyacetates, carboxylates, polycarboxylates, aminopolycarboxylates and polyacetyl carboxylates. The detergent may also be unbuilt, i.e. essentially free of detergent builder.

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose (CMC), poly(vinylpyrrolidone) (PVP), polyethyleneglycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, polymaleates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent composition may contain bleaching agents of the chlorine/bromine-type or the oxygen-type. The bleaching agents may be coated or encapsulated.

Examples of inorganic chlorine/bromine-type bleaches are lithium, sodium or calcium hypochlorite or hypobromite as well as chlorinated trisodium phosphate. Examples of organic chlorine/bromine-type bleaches are heterocyclic N-bromo and N-chloro imides such as trichloroisocyanuric, tribromoisocyanuric, dibromoisocyanuric and dichloroisocyanuric acids, and salts thereof with water solubilizing cations such as potassium and sodium. Hydantoin compounds are also suitable. The bleaching system may also comprise peroxyacids of, e.g., the amide, imide, or sulfone type.

The oxygen-type bleach may be an inorganic persalt, preferably with a bleach activator, or a peroxy acid compound. Examples of inorganic persalts are alkali metal perborates, both tetrahydrates and monohydrates, alkali metal percarbonates, persilicates and perphosphates. The activator may be tetraacetylenediamine (TAED) or nonanoyloxybenzenesulfonate (NOBS).

The enzymes of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative such as, e.g., an aromatic borate ester, and the composition may be formulated as described in, e.g., WO 92/19709 and WO 92/19708. The enzymes of the invention may also be stabilized by adding reversible enzyme inhibitors, e.g., of the protein type as described in EP 0 544 777 B1.

The detergent may also contain other conventional detergent ingredients such as, e.g., fabric conditioners including clays, deflocculant material, foam boosters, foam depressors, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil-redeposition agents, dyes, dehydrating agents, bactericides, optical brighteners, or perfume.

The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. in the range of 7-11.

More specifically, the alpha-amylase of the invention may be incorporated in any of the detergent formulations described in WO 96/23873.

The α -amylases of the invention may be incorporated in concentrations conventionally employed in detergents. It is at present contemplated that, in the detergent composition of the invention, the α -amylase may be added in an amount corresponding to 0.00001-1 mg (calculated as pure enzyme protein) of α -amylase per liter of wash liquor.

The present invention is further illustrated in the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.

EXAMPLES

Host organism:

Escherichia coli SJ2 is described in Diderichsen, B., Wedsted, U., Hedegaard, L., Jensen, B.R., Sjøholm, C. (1990) Journal of Bacteriology, Vol.172, No. 8, p. 4315-4321.

Plasmids:

The gene bank vector was pSJ1678 which is further disclosed in WO94/19454 which is hereby incorporated by reference.

The gene bank vector pSJ1678 is further disclosed in WO 94/19454 which is hereby incorporated by reference.

Model detergent:

A/P (Asia/Pacific) Model Detergent has the following composition: 20% STPP (sodium tripolyphosphate), 25% Na₂SO₄, 15% Na₂CO₃, 20% LAS (linear

alkylbenzene sulfonate, Nansa 80S), 5% C₁₂-C₁₅ alcohol ethoxylate (Dobanol 25-7), 5% Na₂Si₂O₅, 0.3% NaCl.

Example 1

Cloning of alpha-amylase into *E. coli*

5 DNA was isolated from *Bacillus* sp. NCIMB 40916 by the method of Pitcher, D. G., Saunders, N. A., and Owen, R. J. (1989) Lett. Appl. Microbiol. 8, 151-156. Chromosomal DNA was partially digested with the restriction enzyme Sau3AI. The fragments were cloned into the BamHI site of the cloning vector pSJ1678, as shown in Figure 4 and transformed into *Escherichia coli* SJ2, thereby
10 creating a gene library of *Bacillus* sp. NCIMB 40916.

This gene library was screened for alpha amylase activity and the strain showing alpha amylase activity was termed *Escherichia coli* strain NN049489 comprises the full length alpha-amylase of the invention. This strain was deposited and given the accession number DSM 13001. *Escherichia coli* strain DSM 13001
15 (NN049489) harbouring the plasmid termed pJA386 encoding the full length alpha amylase was used for DNA sequencing. Further, *Escherichia coli* strain JA388 comprises a truncated alpha-amylase. This was deposited and given the accession number DSM 12662. *Escherichia coli* strain JA388 harbours the plasmid termed pJA388 encoding the truncated alpha amylase.

20 Example 2

Sequencing of DNA and alpha-amylase

The full length alpha amylase gene cloned in plasmid pJA386 was characterized by DNA sequencing by primer walking, using the Taq deoxyterminal cycle sequencing kit (Perkin Elmer, USA), fluorescent labeled terminators and
25 appropriate oligonucleotides as primers.

Analysis of the sequence data was performed according to Devereux et al. (1984) Nucleic Acids Res. 12, 387-395. The sequence corresponds to the DNA sequence shown in SEQ ID NO: 3. The predicted protein sequence of the full length alpha amylase including the signal peptide and the mature alpha amylase
30 are presented in SEQ ID NO: 4. The deduced N-terminal sequence was verified by sequencing 34 amino acids at the N-terminal of the protein.

Example 3

Production of alpha-amylase

E. coli DSm13001 (NN049489) harboring plasmid pJA386 was cultivated
35 over night in LB-broth containing chloramphenicol 10 µg/ml, 37 °C, 250 rpm. Cells were harvested from 2.7 l culture broth by centrifugation at 6000 rpm for 15

minutes. The intracellular located amylase was released from the cells by using the following osmotic shock procedure:

1) Cells were resuspended and washed in 500 ml 10 mM Tris- HCl, pH 7.0 (EKV-buffer) followed by centrifugation.

2) Cells were resuspended in 75 ml 20% sucrose, 30 mM Tris-HCl pH 8, 1 mM EDTA and added Lysozyme to a concentration of 5 mg/ml.

3) The solution was incubated 15 min on ice followed by centrifugation. The majority of the amylase was now contained in the supernatant.

The supernatant was dialyzed overnight against 10 l in EKV-buffer with one buffer change to decrease the high concentration of sucrose. The solution was filtered through a 0.45 µm membrane vacuum filter.

The enzyme solution was applied on a Pharmacia Q Sepharose column FF previously equilibrated in EKV-buffer, pH 7, and the column was washed with EKV-buffer. Bound proteins were eluted with a linear NaCl gradient from 0-500 mM over 10 column volumes. Amylase containing fractions were pooled and dialyzed against EKV-buffer over night.

The solution was then applied on a Q Sepharose column FF previously equilibrated in EKV-buffer, pH 8, the column was washed with EKV-buffer, and the amylase was eluted with a linear NaCl gradient from 0-500 mM over 10 column volumes. Amylase containing fractions were pooled.

A Phenyl Superose column previously equilibrated in EKV-buffer, pH 8 containing 1 M ammonium sulfate was loaded with the enzyme solution added ammonium sulfate to a concentration of 1 M. Unbound material was washed out with the ammonium sulfate buffer and the column was eluted with a linear NaCl gradient from 1-0 M ammonium sulfate over 20 column volumes. Amylase containing fractions were pooled.

The purified amylase was analyzed by SDS-PAGE and only one band was obtained after staining with Coomassie Blue.

Example 4

Washing test of the full length alpha-amylase (SEQ ID NO: 4)

Washing performance was evaluated by washing soiled test swatches for 15 minutes at 25°C in a detergent solution with the alpha-amylase of the invention.

The detergent used was the A/P Model Detergent described above at 3 g/l having pH 10.5, or a commercial detergent from Malaysia (FAB Total from Colgate) at 3 g/l having a pH of approx. 9.7. The purified amylase of Example 3 was added to the detergent solution at the concentration indicated below. The test swatches were soiled with orange rice starch (CS-28 swatches available from CFT, Center for Test Material, Holland).

After washing, the swatches were evaluated by measuring the remission at 460 nm. The results are expressed as ΔR = remission of the swatch washed with the alpha-amylase minus the remission of a swatch washed at the same conditions without the alpha-amylase.

Alpha-amylase concentration (mg enzyme protein / l)	ΔR Model detergent	ΔR Malaysian detergent
0 (reference)	= 0	= 0
0.1	0.9	1
0.2	1.9	1.3
0.5	3	2.4
1.5	4.1	4.3

- 5 The results are shown in Figures 5 and 6. The results demonstrate that the alpha-amylase of the invention is effective in both detergents at highly alkaline pH.

What is claimed is:

1. An alpha-amylase which is:
 - a) a polypeptide produced by *Bacillus* sp. NCIMB 40916, or
 - b) a polypeptide having an amino acid sequence as shown in positions 1-556 of SEQ ID NO: 4, or
 - c) a polypeptide encoded by the alpha-amylase encoding part of the DNA sequence cloned into a plasmid present in *Escherichia coli* DSM 13001 (NN049489), or
 - d) an analogue of the polypeptide defined in (a) or (b) which:
 - i) is at least 60 % homologous with said polypeptide, or
 - ii) is derived from said polypeptide by substitution, deletion and/or insertion of one or more amino acids.
2. An alpha-amylase which has an activity at pH 10.5 which is at least two times higher than the activity at pH 7.3 when measured at 37°C.
3. An alpha-amylase which has an activity at pH 9.5 which is at least 4 times higher than the activity at pH 7.3 when measured at 37°C.
4. The alpha-amylase of claim 1 which is from a strain of *Bacillus*, preferably *Bacillus* sp. NCIMB 40916.
5. The alpha-amylase of claim 1 which retains more than 90 % of its activity after 20 minutes incubation at 25°C in a solution of 3 g/l of a test detergent containing 20% STPP, 25% Na₂SO₄, 15% Na₂CO₃, 20% LAS, 5% C12-C15 alcohol ethoxylate, 5% Na₂Si₂O₅, 0.3% NaCl at pH 10.5 and 6 degrees German hardness, and retains less than 90 % of its activity after 20 minutes incubation at 30°C in the same solution.
6. The alpha-amylase of claim 1 which has a molecular weight of about 55 kDa as determined by SDS-PAGE.
7. The alpha-amylase of claim 1 which has an iso-electric point of about 5 as determined by isoelectric focusing.
8. The alpha-amylase of claim 1 in the form of a detergent additive which is a non-dusting granulate or a stabilized liquid.

9. An isolated DNA sequence which encodes the alpha-amylase of claim 1.
10. The DNA sequence according to claim 9, which is from a bacterium, preferably from *Bacillus*, most preferably from the strain NCIMB 40916.
11. A recombinant expression vector comprising the DNA sequence of claim 9.
- 5 12. A cell transformed with the DNA sequence of claim 9 or the recombinant expression vector of claim 11.
13. The cell of claim 12, which is a prokaryotic cell, in particular a bacterial cell or an endogenous cell from which said DNA sequence originates.
- 10 14. The cell of claim 13, wherein the cell belongs to *Bacillus* or *Escherichia*, preferably *E. coli*.
- 15 15. A method of producing an alpha-amylase, comprising cultivating a cell of claim 12 under conditions permitting the production of the alpha-amylase, and recovering the alpha-amylase from the culture.
16. A method for producing the alpha-amylase of claim 1, comprising cultivating an amylase-producing strain of *Bacillus* in a suitable nutrient medium, and recovering the alpha-amylase from the culture medium.
17. A detergent composition comprising the alpha-amylase of claim 1 and a surfactant.
18. The detergent composition of claim 18 which has a pH of 8.5-11 in aqueous solution, preferably pH 9-10.5
- 20 19. The detergent composition of claim 18 which is a laundry detergent.

ABSTRACT OF THE DISCLOSURE

The present invention relates to amylases having improved washing performance in an alkaline detergent solution at low temperature. More specifically, the present invention provides novel α -amylases from *Bacillus sp.* with improved performance in alkaline solutions, especially in alkaline detergent solutions at pH around 9-11.

5

SEQUENCE LISTING

5 <110> Outtrup, Helle
 Nielsen, Bjarne Roenfeldt
 Hedegaard, Lisbeth
 Andersen, Jens Toenne

10 <120> Alkaline Bacillus Amylase

15 <130> 5442.400-US
 <160> 4

20 <170> FastSEQ for Windows Version 3.0
 <210> 1
 <211> 1646
 <212> DNA
 <213> Bacillus sp.

25 <220>
 <221> CDS
 <222> (1)...(1646)

30 <221> sig_peptide
 <222> (1)...(93)

35 <221> mat_peptide
 <222> (94)...(1646)

<400> 1

atg caa aac aca gcg aaa aac tcc atc tgg cag agg gtg cgc cac agc 48
 Met Gln Asn Thr Ala Lys Asn Ser Ile Trp Gln Arg Val Arg His Ser
 -30 -25 -20

gcc att gcc tta tcc gct ctc agt tta tcc ttt ggc ctg cag gcc agc 96

[illegible]

	tgg ggc tac ttg tgg cac gac ttt gac tgg aac tgg acc gcg ttt aat	576
	Trp Gly Tyr Leu Trp His Asp Phe Asp Trp Asn Trp Thr Ala Phe Asn	
	150 155 160	
5	ggc tcc gac aat cag ctc tac ccc ggc aaa tgg tgg ggc aat acc ttc	624
	Gly Ser Asp Asn Gln Leu Tyr Pro Gly Lys Trp Trp Gly Asn Thr Phe	
	165 170 175	
10	cac ttc cct tat ttg atg ggt gag gat gtc gat tac aac cgc ttt gaa	672
	His Phe Pro Tyr Leu Met Gly Glu Asp Val Asp Tyr Asn Arg Phe Glu	
	180 185 190	
15	gtg cag cag gaa atg aaa gcc tgg ggc gag tgg atc atc aac agc gtt	720
	Val Gln Gln Glu Met Lys Ala Trp Gly Glu Trp Ile Ile Asn Ser Val	
	195 200 205	
20	ggc ttt agc ggc ttt cgg atg gat gcc atc gcc cat gtc gat acc gat	768
	Gly Phe Ser Gly Phe Arg Met Asp Ala Ile Ala His Val Asp Thr Asp	
	210 215 220 225	
25	ttt acc cgt gac tgg atc aat cac gtg cag tgg gcc acc agt gag gat	816
	Phe Thr Arg Asp Trp Ile Asn His Val Gln Trp Ala Thr Ser Glu Asp	
	230 235 240	
30	gtg ttc ttt gtc gct gaa gcc tgg gtc agt gat atc aac ggc tat ctg	864
	Val Phe Phe Val Ala Glu Ala Trp Val Ser Asp Ile Asn Gly Tyr Leu	
	245 250 255	
35	gat gca gtc aat acg ccg cat ttg cgc gct ttt gat ttc aat ttg cgc	912
	Asp Ala Val Asn Thr Pro His Leu Arg Ala Phe Asp Phe Asn Leu Arg	
	260 265 270	
40	gaa gac ttc gtt gct tta agc agc ggt agc aaa gac atg cgt tgg tgg	960
	Glu Asp Phe Val Ala Leu Ser Ser Gly Ser Lys Asp Met Arg Trp Trp	
	275 280 285	
45	ggc ggt ctg gtc aat agc cag cac cgt gat cgg gcg gtc act ttt gtc	1008
	Gly Gly Leu Val Asn Ser Gln His Arg Asp Arg Ala Val Thr Phe Val	
	290 295 300 305	

gat aac cac gat acc agc cgg gcc ggc aac cct tat ggc atg ccg cag 1056
 Asp Asn His Asp Thr Ser Arg Ala Gly Asn Pro Tyr Gly Met Pro Gln
 310 315 320

5

gtg atc aac tac aag aac cag gcc tac gct tac att ctg ttg cgt gag 1104
 Val Ile Asn Tyr Lys Asn Gln Ala Tyr Ala Tyr Ile Leu Leu Arg Glu
 325 330 335

10

cat ggg gtg ccg act gtg ttt gcc cgc gat tac gac gaa ttt ggc atg 1152
 His Gly Val Pro Thr Val Phe Ala Arg Asp Tyr Asp Glu Phe Gly Met
 340 345 350

15

gcg cca acg ctg gat aaa ttg att gag gcg cgc cgc tac ttt gct tat 1200
 Ala Pro Thr Leu Asp Lys Leu Ile Glu Ala Arg Arg Tyr Phe Ala Tyr
 355 360 365

20

ggt cct ggc cat gag tac tcc ggc aat acc gag gcc gtc tac gcc tat 1248
 Gly Pro Gly His Glu Tyr Ser Gly Asn Thr Glu Ala Val Tyr Ala Tyr
 370 375 380 385

25

gtg cgc gaa ggg ctt agc act gtg ccg ggt acc ggt ctg gtg atg ctg 1296
 Val Arg Glu Gly Leu Ser Thr Val Pro Gly Thr Gly Leu Val Met Leu
 390 395 400

30

ata tcg ggt cga aac tgg ggt ggt cag cag tcg ttc acc atc aac agc 1344
 Ile Ser Gly Arg Asn Trp Gly Gly Gln Gln Ser Phe Thr Ile Asn Ser
 405 410 415

35

cac cag ccg aat acc acc ttt tac gat tat acc ggc aat gtt agc ggc 1392
 His Gln Pro Asn Thr Thr Phe Tyr Asp Tyr Thr Gly Asn Val Ser Gly
 420 425 430

acg gtg acc acc aat gcg cag ggc tat ggc agc ttc ccg gtc act atg 1440
 Thr Val Thr Thr Asn Ala Gln Gly Tyr Gly Ser Phe Pro Val Thr Met
 435 440 445

acg gaa agt acc ggt tgg tca gtc tgg gta cca caa tcc aat ggt ggc 1488
 Thr Glu Ser Thr Gly Trp Ser Val Trp Val Pro Gln Ser Asn Gly Gly

	450	455	460	465	
	act cag ccg gga tcc att acc ctg cgg atg acc aag gat gtt ggc tat				1536
	Thr Gln Pro Gly Ser Ile Thr Leu Arg Met Thr Lys Asp Val Gly Tyr				
5	470	475	480		
	ggc ttt tcg ttg ttc ttc acc ggc agc agt gcg gaa ctg acc aac tgg				1584
	Gly Phe Ser Leu Phe Phe Thr Gly Ser Ser Ala Glu Leu Thr Asn Trp				
	485	490	495		
10					
	ggc ggc ggt att gaa ggc acc tgg aca tcc ggt aat gtc tgg gaa gtg				1632
	Gly Gly Gly Ile Glu Gly Thr Trp Thr Ser Gly Asn Val Trp Glu Val				
	500	505	510		
15					
	acc atc ccg gat cc				1646
	Thr Ile Pro Asp				
	515				
20					
	<210> 2				
	<211> 548				
	<212> PRT				
	<213> Bacillus sp.				
25					
	<220>				
	<221> SIGNAL				
	<222> (1)...(31)				
	<400> 2				
30					
	Met Gln Asn Thr Ala Lys Asn Ser Ile Trp Gln Arg Val Arg His Ser				
	-30	-25	-20		
	Ala Ile Ala Leu Ser Ala Leu Ser Leu Ser Phe Gly Leu Gln Ala Ser				
	-15	-10	-5	1	
	Glu Leu Pro Gln Ile Pro Pro Gln Gln Val Asn Asn Thr Met Tyr Gln				
35	5	10	15		
	Ala Phe Tyr Trp Asp Ala Tyr Pro Gly Leu Trp Ala Asn Leu Pro Ala				
	20	25	30		
	Met Ala Ala Pro Leu Ala Glu Arg Gly Ile Thr Ser Met Trp Leu Pro				
	35	40	45		

5442.400-US
 23
 1536
 1584
 1632
 1646
 <210> 2
 <211> 548
 <212> PRT
 <213> Bacillus sp.
 <220>
 <221> SIGNAL
 <222> (1)...(31)
 <400> 2

Pro Ala Ala Lys Gly Met Asn Gly Thr Phe Ser Val Gly Tyr Asp Val
 50 55 60 65
 Tyr Asp Phe Trp Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Thr Ala
 70 75 80
 5 Thr Arg Tyr Gly Thr Arg Gln Gln Leu Gln Gln Ala Leu Ser Ala Leu
 85 90 95
 Asp Gln Leu Gly Ile Gln Ala Tyr Phe Asp Val Val Phe Asn His Arg
 100 105 110
 Met Gly Ala Asp Ala Gln Glu Asn Ile Pro Gly Phe Gly Leu Ala Trp
 10 115 120 125
 Thr Glu Tyr His Leu Gln Gly Arg Gln Ala His Tyr Thr Gln Gln Asn
 130 135 140 145
 Trp Gly Tyr Leu Trp His Asp Phe Asp Trp Asn Trp Thr Ala Phe Asn
 150 155 160
 15 Gly Ser Asp Asn Gln Leu Tyr Pro Gly Lys Trp Trp Gly Asn Thr Phe
 165 170 175
 His Phe Pro Tyr Leu Met Gly Glu Asp Val Asp Tyr Asn Arg Phe Glu
 180 185 190
 Val Gln Gln Glu Met Lys Ala Trp Gly Glu Trp Ile Ile Asn Ser Val
 20 195 200 205
 Gly Phe Ser Gly Phe Arg Met Asp Ala Ile Ala His Val Asp Thr Asp
 210 215 220 225
 Phe Thr Arg Asp Trp Ile Asn His Val Gln Trp Ala Thr Ser Glu Asp
 230 235 240
 25 Val Phe Phe Val Ala Glu Ala Trp Val Ser Asp Ile Asn Gly Tyr Leu
 245 250 255
 Asp Ala Val Asn Thr Pro His Leu Arg Ala Phe Asp Phe Asn Leu Arg
 260 265 270
 Glu Asp Phe Val Ala Leu Ser Ser Gly Ser Lys Asp Met Arg Trp Trp
 30 275 280 285
 Gly Gly Leu Val Asn Ser Gln His Arg Asp Arg Ala Val Thr Phe Val
 290 295 300 305
 Asp Asn His Asp Thr Ser Arg Ala Gly Asn Pro Tyr Gly Met Pro Gln
 310 315 320
 35 Val Ile Asn Tyr Lys Asn Gln Ala Tyr Ala Tyr Ile Leu Leu Arg Glu
 325 330 335
 His Gly Val Pro Thr Val Phe Ala Arg Asp Tyr Asp Glu Phe Gly Met
 340 345 350
 Ala Pro Thr Leu Asp Lys Leu Ile Glu Ala Arg Arg Tyr Phe Ala Tyr

355 360 365
 Gly Pro Gly His Glu Tyr Ser Gly Asn Thr Glu Ala Val Tyr Ala Tyr
 370 375 380 385
 Val Arg Glu Gly Leu Ser Thr Val Pro Gly Thr Gly Leu Val Met Leu
 5 390 395 400
 Ile Ser Gly Arg Asn Trp Gly Gly Gln Gln Ser Phe Thr Ile Asn Ser
 405 410 415
 His Gln Pro Asn Thr Thr Phe Tyr Asp Tyr Thr Gly Asn Val Ser Gly
 420 425 430
 10 Thr Val Thr Thr Asn Ala Gln Gly Tyr Gly Ser Phe Pro Val Thr Met
 435 440 445
 Thr Glu Ser Thr Gly Trp Ser Val Trp Val Pro Gln Ser Asn Gly Gly
 450 455 460 465
 Thr Gln Pro Gly Ser Ile Thr Leu Arg Met Thr Lys Asp Val Gly Tyr
 15 470 475 480
 Gly Phe Ser Leu Phe Phe Thr Gly Ser Ser Ala Glu Leu Thr Asn Trp
 485 490 495
 Gly Gly Gly Ile Glu Gly Thr Trp Thr Ser Gly Asn Val Trp Glu Val
 500 505 510
 20 Thr Ile Pro Asp
 515

 <210> 3
 <211> 1764
 25 <212> DNA
 <213> Bacillus sp.

 <220>
 <221> CDS
 30 <222> (1)...(1764)

 <221> sig_peptide
 <222> (1)...(93)

 35 <221> mat_peptide
 <222> (94)...(1764)

 <400> 3
 atg caa aac aca gcg aaa aac tcc atc tgg cag agg gtg cgc cac agc

	Met Gln Asn Thr Ala Lys Asn Ser Ile Trp Gln Arg Val Arg His Ser	
	-30 -25 -20	
5	gcc att gcc tta tcc gct ctc agt tta tcc ttt ggc ctg cag gcc agc Ala Ile Ala Leu Ser Ala Leu Ser Leu Ser Phe Gly Leu Gln Ala Ser	96
	-15 -10 -5 1	
10	gag tta cca caa att cca cca cag cag gtg aac aac acc atg tac cag Glu Leu Pro Gln Ile Pro Pro Gln Gln Val Asn Asn Thr Met Tyr Gln	144
	5 10 15	
15	gca ttt tat tgg gat gcc tac cct ggc ctt tgg gcc aat tta ccg gcc Ala Phe Tyr Trp Asp Ala Tyr Pro Gly Leu Trp Ala Asn Leu Pro Ala	192
	20 25 30	
20	atg gcg gcc cct ttg gcc gag cgt ggc att acc tcg atg tgg ttg ccg Met Ala Ala Pro Leu Ala Glu Arg Gly Ile Thr Ser Met Trp Leu Pro	240
	35 40 45	
25	ccc gcc gcc aaa ggc atg aat ggt act ttc agt gtc ggt tac gat gta Pro Ala Ala Lys Gly Met Asn Gly Thr Phe Ser Val Gly Tyr Asp Val	288
	50 55 60 65	
30	tac gat ttc tgg gat ctg ggc gag ttt aac caa aaa ggc acc acc gcc Tyr Asp Phe Trp Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Thr Ala	336
	70 75 80	
35	acc cgt tac ggt act cgt cag cag ctg caa caa gca ctg agt gct ctg Thr Arg Tyr Gly Thr Arg Gln Gln Leu Gln Gln Ala Leu Ser Ala Leu	384
	85 90 95	
40	gac caa ctg ggt att cag gcc tat ttt gat gtg gtg ttt aac cac cgc Asp Gln Leu Gly Ile Gln Ala Tyr Phe Asp Val Val Phe Asn His Arg	432
	100 105 110	
45	atg ggc gcc gat gca cag gag aat att cct ggc ttt ggc ctg gcc tgg Met Gly Ala Asp Ala Gln Glu Asn Ile Pro Gly Phe Gly Leu Ala Trp	480
	115 120 125	

	acc gag tat cat ctg caa ggt cgt cag gcg cat tat acc cag caa aac	528
	Thr Glu Tyr His Leu Gln Gly Arg Gln Ala His Tyr Thr Gln Gln Asn	
	130 135 140 145	
5	tgg ggc tac ttg tgg cac gac ttt gac tgg aac tgg acc gcg ttt aat	576
	Trp Gly Tyr Leu Trp His Asp Phe Asp Trp Asn Trp Thr Ala Phe Asn	
	150 155 160	
	ggc tcc gac aat cag ctc tac ccc ggc aaa tgg tgg ggc aat acc ttc	624
10	Gly Ser Asp Asn Gln Leu Tyr Pro Gly Lys Trp Trp Gly Asn Thr Phe	
	165 170 175	
	cac ttc cct tat ttg atg ggt gag gat gtc gat tac aac cgc ttt gaa	672
	His Phe Pro Tyr Leu Met Gly Glu Asp Val Asp Tyr Asn Arg Phe Glu	
15	180 185 190	
	gtg cag cag gaa atg aaa gcc tgg ggc gag tgg atc atc aac agc gtt	720
	Val Gln Gln Glu Met Lys Ala Trp Gly Glu Trp Ile Ile Asn Ser Val	
	195 200 205	
20	ggc ttt agc ggc ttt cgg atg gat gcc atc gcc cat gtc gat acc gat	768
	Gly Phe Ser Gly Phe Arg Met Asp Ala Ile Ala His Val Asp Thr Asp	
	210 215 220 225	
25	ttt acc cgt gac tgg atc aat cac gtg cag tgg gcc acc agt gag gat	816
	Phe Thr Arg Asp Trp Ile Asn His Val Gln Trp Ala Thr Ser Glu Asp	
	230 235 240	
	gtg ttc ttt gtc gct gaa gcc tgg gtc agt gat atc aac ggc tat ctg	864
30	Val Phe Phe Val Ala Glu Ala Trp Val Ser Asp Ile Asn Gly Tyr Leu	
	245 250 255	
	gat gca gtc aat acg ccg cat ttg cgc gct ttt gat ttc aat ttg cgc	912
	Asp Ala Val Asn Thr Pro His Leu Arg Ala Phe Asp Phe Asn Leu Arg	
35	260 265 270	
	gaa gac ttc gtt gct tta agc agc ggt agc aaa gac atg cgt tgg tgg	960
	Glu Asp Phe Val Ala Leu Ser Ser Gly Ser Lys Asp Met Arg Trp Trp	
	275 280 285	

5 ggc ggt ctg gtc aat agc cag cac cgt gat cgg gcg gtc act ttt gtc 1008
 Gly Gly Leu Val Asn Ser Gln His Arg Asp Arg Ala Val Thr Phe Val
 290 295 300 305

10 gat aac cac gat acc agc cgg gcc ggc aac cct tat ggc atg ccg cag 1056
 Asp Asn His Asp Thr Ser Arg Ala Gly Asn Pro Tyr Gly Met Pro Gln
 310 315 320

15 gtg atc aac tac aag aac cag gcc tac gct tac att ctg ttg cgt gag 1104
 Val Ile Asn Tyr Lys Asn Gln Ala Tyr Ala Tyr Ile Leu Leu Arg Glu
 325 330 335

20 cat ggg gtg ccg act gtg ttt gcc cgc gat tac gac gaa ttt ggc atg 1152
 His Gly Val Pro Thr Val Phe Ala Arg Asp Tyr Asp Glu Phe Gly Met
 340 345 350

25 gcg cca acg ctg gat aaa ttg att gag gcg cgc cgc tac ttt gct tat 1200
 Ala Pro Thr Leu Asp Lys Leu Ile Glu Ala Arg Arg Tyr Phe Ala Tyr
 355 360 365

30 ggt cct ggc cat gag tac tcc ggc aat acc gag gcc gtc tac gcc tat 1248
 Gly Pro Gly His Glu Tyr Ser Gly Asn Thr Glu Ala Val Tyr Ala Tyr
 370 375 380 385

35 gtg cgc gaa ggg ctt agc act gtg ccg ggt acc ggt ctg gtg atg ctg 1296
 Val Arg Glu Gly Leu Ser Thr Val Pro Gly Thr Gly Leu Val Met Leu
 390 395 400

40 ata tcg ggt cga aac tgg ggt ggt cag cag tcg ttc acc atc aac agc 1344
 Ile Ser Gly Arg Asn Trp Gly Gly Gln Gln Ser Phe Thr Ile Asn Ser
 405 410 415

45 cac cag ccg aat acc acc ttt tac gat tat acc ggc aat gtt agc ggc 1392
 His Gln Pro Asn Thr Thr Phe Tyr Asp Tyr Thr Gly Asn Val Ser Gly
 420 425 430

50 acg gtg acc acc aat gcg cag ggc tat ggc agc ttc ccg gtc act atg 1440
 Thr Val Thr Thr Asn Ala Gln Gly Tyr Gly Ser Phe Pro Val Thr Met

	435	440	445	
	acg gaa agt acc ggt tgg tca gtc tgg gta cca caa tcc aat ggt ggc			1488
	Thr Glu Ser Thr Gly Trp Ser Val Trp Val Pro Gln Ser Asn Gly Gly			
5	450	455	460	465
	act cag ccg gga tcc att acc ctg cgg atg acc aag gat gtt ggc tat			1536
	Thr Gln Pro Gly Ser Ile Thr Leu Arg Met Thr Lys Asp Val Gly Tyr			
	470	475	480	
10				
	ggc ttt tcg ttg ttc ttc acc ggc agc agt gcg gaa ctg acc aac tgg			1584
	Gly Phe Ser Leu Phe Phe Thr Gly Ser Ser Ala Glu Leu Thr Asn Trp			
	485	490	495	
15				
	ggc ggc ggt att gaa ggc acc tgg aca tcc ggt aat gtc tgg gaa gtg			1632
	Gly Gly Gly Ile Glu Gly Thr Trp Thr Ser Gly Asn Val Trp Glu Val			
	500	505	510	
	acc atc ccg gat ccg ggc aac ttt gaa tgg aaa acc cgt aaa ggc cca			1680
20				
	Thr Ile Pro Asp Pro Gly Asn Phe Glu Trp Lys Thr Arg Lys Gly Pro			
	515	520	525	
	acc ggt ggc agt ggt cag gac tgg gaa agt ggc agc aac cac aat cag			1728
	Thr Gly Gly Ser Gly Gln Asp Trp Glu Ser Gly Ser Asn His Asn Gln			
25	530	535	540	545
	acc aat ttg cac ccc agt ttt aat ggt ggg ttt taa			1764
	Thr Asn Leu His Pro Ser Phe Asn Gly Gly Phe *			
	550	555		
30				
	<210> 4			
	<211> 587			
	<212> PRT			
35	<213> Bacillus sp.			
	<220>			
	<221> SIGNAL			
	<222> (1)...(31)			

<400> 4

Met Gln Asn Thr Ala Lys Asn Ser Ile Trp Gln Arg Val Arg His Ser
 -30 -25 -20
 5 Ala Ile Ala Leu Ser Ala Leu Ser Leu Ser Phe Gly Leu Gln Ala Ser
 -15 -10 -5 1
 Glu Leu Pro Gln Ile Pro Pro Gln Gln Val Asn Asn Thr Met Tyr Gln
 5 10 15
 Ala Phe Tyr Trp Asp Ala Tyr Pro Gly Leu Trp Ala Asn Leu Pro Ala
 10 20 25 30
 Met Ala Ala Pro Leu Ala Glu Arg Gly Ile Thr Ser Met Trp Leu Pro
 35 40 45
 Pro Ala Ala Lys Gly Met Asn Gly Thr Phe Ser Val Gly Tyr Asp Val
 50 55 60 65
 15 Tyr Asp Phe Trp Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Thr Ala
 70 75 80
 Thr Arg Tyr Gly Thr Arg Gln Gln Leu Gln Gln Ala Leu Ser Ala Leu
 85 90 95
 Asp Gln Leu Gly Ile Gln Ala Tyr Phe Asp Val Val Phe Asn His Arg
 100 105 110
 20 Met Gly Ala Asp Ala Gln Glu Asn Ile Pro Gly Phe Gly Leu Ala Trp
 115 120 125
 Thr Glu Tyr His Leu Gln Gly Arg Gln Ala His Tyr Thr Gln Gln Asn
 130 135 140 145
 25 Trp Gly Tyr Leu Trp His Asp Phe Asp Trp Asn Trp Thr Ala Phe Asn
 150 155 160
 Gly Ser Asp Asn Gln Leu Tyr Pro Gly Lys Trp Trp Gly Asn Thr Phe
 165 170 175
 His Phe Pro Tyr Leu Met Gly Glu Asp Val Asp Tyr Asn Arg Phe Glu
 180 185 190
 30 Val Gln Gln Glu Met Lys Ala Trp Gly Glu Trp Ile Ile Asn Ser Val
 195 200 205
 Gly Phe Ser Gly Phe Arg Met Asp Ala Ile Ala His Val Asp Thr Asp
 210 215 220 225
 35 Phe Thr Arg Asp Trp Ile Asn His Val Gln Trp Ala Thr Ser Glu Asp
 230 235 240
 Val Phe Phe Val Ala Glu Ala Trp Val Ser Asp Ile Asn Gly Tyr Leu
 245 250 255
 Asp Ala Val Asn Thr Pro His Leu Arg Ala Phe Asp Phe Asn Leu Arg

	260	265	270
	Glu Asp Phe Val Ala Leu Ser Ser Gly Ser Lys Asp Met Arg Trp Trp		
	275	280	285
	Gly Gly Leu Val Asn Ser Gln His Arg Asp Arg Ala Val Thr Phe Val		
5	290	295	300
	305		
	Asp Asn His Asp Thr Ser Arg Ala Gly Asn Pro Tyr Gly Met Pro Gln		
	310	315	320
	Val Ile Asn Tyr Lys Asn Gln Ala Tyr Ala Tyr Ile Leu Leu Arg Glu		
	325	330	335
10	340	345	350
	His Gly Val Pro Thr Val Phe Ala Arg Asp Tyr Asp Glu Phe Gly Met		
	Ala Pro Thr Leu Asp Lys Leu Ile Glu Ala Arg Arg Tyr Phe Ala Tyr		
	355	360	365
	Gly Pro Gly His Glu Tyr Ser Gly Asn Thr Glu Ala Val Tyr Ala Tyr		
15	370	375	380
	385		
	Val Arg Glu Gly Leu Ser Thr Val Pro Gly Thr Gly Leu Val Met Leu		
	390	395	400
	Ile Ser Gly Arg Asn Trp Gly Gly Gln Gln Ser Phe Thr Ile Asn Ser		
	405	410	415
20	420	425	430
	His Gln Pro Asn Thr Thr Phe Tyr Asp Tyr Thr Gly Asn Val Ser Gly		
	Thr Val Thr Thr Asn Ala Gln Gly Tyr Gly Ser Phe Pro Val Thr Met		
	435	440	445
	Thr Glu Ser Thr Gly Trp Ser Val Trp Val Pro Gln Ser Asn Gly Gly		
25	450	455	460
	465		
	Thr Gln Pro Gly Ser Ile Thr Leu Arg Met Thr Lys Asp Val Gly Tyr		
	470	475	480
	Gly Phe Ser Leu Phe Phe Thr Gly Ser Ser Ala Glu Leu Thr Asn Trp		
	485	490	495
30	500	505	510
	Gly Gly Gly Ile Glu Gly Thr Trp Thr Ser Gly Asn Val Trp Glu Val		
	Thr Ile Pro Asp Pro Gly Asn Phe Glu Trp Lys Thr Arg Lys Gly Pro		
	515	520	525
	Thr Gly Gly Ser Gly Gln Asp Trp Glu Ser Gly Ser Asn His Asn Gln		
35	530	535	540
	545		
	Thr Asn Leu His Pro Ser Phe Asn Gly Gly Phe		
	550	555	




Fig.1




Fig.2




Fig.3




Fig. 4




Fig.5




Fig.6

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Alkaline Bacillus Amylase

the specification of which (check only one item below):

☐ is attached hereto

☒ was filed as United States application

Application No. to be assigned

on August 24, 1999

and was amended

on _____

☐ was filed as PCT international application

Number _____

on _____

and was amended under PCT Article 19

on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Denmark	0228/98	February 18, 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
U.S.A.	60/146,297	February 27, 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to PCT International Applications)				Attorney's Docket Number 5442.400-US	
I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this applications is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS			STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	Patented	Pending	Abandoned	
09/249,558	February 12, 1999		X		
PCT APPLICATIONS DESIGNATING THE U.S.					
APPLICATION NO.	FILING DATE	US SERIAL NUMBERS ASSIGNED (if any)			
POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.					
Steve T. Zelson Reg. No. 30,335	Elias J. Lambiris Reg. No. 33,728	Valeta A. Gregg Reg. No. 35,127	Carol E. Rozek Reg. No. 36,993	Robert L. Starnes Reg. No. 41,324	Reza Green Reg. No. 38,475
Send Correspondence to: Steve T. Zelson, Esq. Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, New York 10174-6400			Direct Telephone Calls To: Steve T. Zelson (212) 867-0123		
	Full Name of Inventor	Family Name Outtrup	First Given Name Helle	Second Given Name	
	Residence & Citizenship	City DK-2750 Ballerup	State or Foreign Country Denmark	Country of Citizenship Denmark	
	Post Office Address	Post Office Address Syvendehusvej 46	City DK-2750 Ballerup	State & Zip Code/Country Denmark	
2	Full Name of Inventor	Family Name Nielsen	First Given Name Bjarne	Second Given Name Rønfeldt	
	Residence & Citizenship	City DK-2830 Virum	State or Foreign Country Denmark	Country of Citizenship Denmark	
	Post Office Address	Post Office Address Ligustervænget 27	City DK-2830 Virum	State & Zip Code/Country Denmark	
3	Full Name of Inventor	Family Name Hedegaard	First Given Name Lisbeth	Second Given Name	
	Residence & Citizenship	City 2942 Skodsborg	State or Foreign Country Denmark	Country of Citizenship Denmark	
	Post Office Address	Post Office Address Køromvej 16	City 2942 Skodsborg	State & Zip Code/Country Denmark	
4	Full Name of Inventor	Family Name Andersen	First Given Name Jens	Second Given Name Toenne	
	Residence & Citizenship	City DK-2850 Naerum	State or Foreign Country Denmark	Country of Citizenship Denmark	
	Post Office Address	Post Office Address Skyttebjerg 85	City DK-2850 Naerum	State & Zip Code/Country Denmark	

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to PCT International Applications)				Attorney's Docket Number 5442.400-US	
5	Full Name of Inventor	Family Name	First Given Name	Second Given Name	
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship	
	Post Office Address	Post Office Address	City	State & Zip Code/Country	
6	Full Name of Inventor	Family Name	First Given Name	Second Given Name	
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship	
	Post Office Address	Post Office Address	City	State & Zip Code/Country	
7	Full Name of Inventor	Family Name	First Given Name	Second Given Name	
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship	
	Post Office Address	Post Office Address	City	State & Zip Code/Country	
8	Full Name of Inventor	Family Name	First Given Name	Second Given Name	
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship	
	Post Office Address	Post Office Address	City	State & Zip Code/Country	
	Full Name of Inventor	Family Name	First Given Name	Second Given Name	
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship	
	Post Office Address	Post Office Address	City	State & Zip Code/Country	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.</p>					
Signature of Inventor 1		Signature of Inventor 2		Signature of Inventor 3	
Date		Date		Date	
Signature of Inventor 4		Signature of Inventor 5		Signature of Inventor 6	
Date		Date		Date	
Signature of Inventor 7		Signature of Inventor 8		Signature of Inventor 9	
Date		Date		Date	